CYP27A1 and chronic kidney disease: A post hoc analysis of 3 phase III multicenter, randomized, double-blind, controlled trials including 852 patients with CKD and eGFR ≥ 30 mL/min/1.73 m2 showed that treatment with risedronate (either 2.5 mg once daily or 17.5 mg once weekly) is safe and effective regardless of the CKD stage, leading to significant increase in lumbar spine BMD and a significant decrease in bone turnover markers (urine NTX, urine CTX, and BSAP) after 48 weeks (365).